Q32 Bio is a biotechnology company developing biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to re-balance the immune system in severe autoimmune and inflammatory diseases. Q32 Bio is addressing immune dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.

LocationCambridge, MA
CEOMike Broxson
Websitewww.Q32bio.com